Seymour, Lesley

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 5,419

Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

Pignon, J.-P., Tribodet, H., Scagliotti, G. V., Douillard, J.-Y., Shepherd, F. A., Stephens, R. J., Dunant, A., Torri, V., Rosell, R., Seymour, L., et al. (2008) · Journal of Clinical Oncology

Lung Cancer Diagnosis and TreatmentLung Cancer Research Studies

Cited by 2,642

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., Lin, N. U., Litière, S., Dancey, J., Chen, A., et al. (2017) · The Lancet Oncology

Cancer Immunotherapy and BiomarkersMedical Imaging Techniques and Applications

Cited by 2,472

RECIST 1.1—Update and clarification: From the RECIST committee

Schwartz, L. H., Litière, S., de Vries, E., Ford, R., Gwyther, S., Mandrekar, S., Shankar, L., Bogaerts, J., Chen, A., Dancey, J., et al. (2016) · European Journal of Cancer

Medical Imaging Techniques and ApplicationsStatistical Methods in Clinical Trials

Cited by 1,906

Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21

Zhu, C.-Q., da Cunha Santos, G., Ding, K., Sakurada, A., Cutz, J.-C., Liu, N., Zhang, T., Marrano, P., Whitehead, M., Squire, J. A., et al. (2008) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 661

Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies

Hilton, J., Gelmon, K., Bedard, P. L., Tu, D., Xu, H., Tinker, A. V., Goodwin, R., Laurie, S. A., Jonker, D., Hansen, A. R., et al. (2022) · Nature Communications

DNA and Nucleic Acid ChemistryPARP inhibition in cancer therapy

Cited by 155

Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non–Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy

Shepherd, F. A., Lacas, B., Le Teuff, G., Hainaut, P., Jänne, P. A., Pignon, J.-P., Le Chevalier, T., Seymour, L., Douillard, J.-Y., Graziano, S., et al. (2017) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 124

Pooled analysis of the prognostic and predictive value of KRAS mutation status and mutation subtype in patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors

Zer, A., Ding, K., Lee, S. M., Goss, G. D., Seymour, L., Ellis, P. M., Hackshaw, A., Bradbury, P. A., Han, L., O’Callaghan, C. J., et al. (2016) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 56